Clinical Trials
29 trialsThiotepa-Containing Conditioning Regimen for Allogeneic HSCT in Chronic Myelomonocytic Leukemia
Peking University People's Hospital
Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases
Masonic Cancer Center, University of Minnesota
Haplo-Cord HSCT for AML/MDS
Fujian Medical University Union Hospital
TBF-AML
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts
H. Lee Moffitt Cancer Center and Research Institute
Anti-Mesothelin CAR-T Cell Injection in Patients With Mesothelin-positive Advanced Malignant Solid Tumors
Zhejiang University
MT027 Cell Injection in Patients With Advanced Primary or Secondary Peritoneal Tumors
Ruijin Hospital
Haploidentical (Half-matched) Related Donor Stem Cell Transplantation Using Killer Immunoglobulin-like Receptors in Addition to Normal Selection Factors to Determine the Best Donor
Memorial Sloan Kettering Cancer Center
LCAR-M61S and LCAR-M61D in Treatment of Relapsed/Refractory Multiple Myeloma
The First Affiliated Hospital with Nanjing Medical University
Efficacy and Safety of MTBF Conditioning Regimen for Salvageable Allo-HSCT in the Treatment of R/R AML
First Affiliated Hospital Xi'an Jiaotong University
The Safety and Efficacy of Double-target CART-19 and 20 Cells in Non-Hodgkin's Lymphoma (NHL)
Henan Cancer Hospital
GZL Sequential CD19/CD22 CAR-T in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
The First Affiliated Hospital of Soochow University
UCAML
Baylor College of Medicine
Combined Haploidentical-Cord Blood Transplantation for Adults and Children
University of Chicago
Chemotherapy Followed by Allogeneic Stem Cell Transplantation for Hematologic Malignancies
Dartmouth-Hitchcock Medical Center
Clinical Study of CAR-BCMA T Cells in Patients With Refractory or Relapsed Multiple Myeloma
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors
First Affiliated Hospital of Wenzhou Medical University
THALLO
Baylor College of Medicine
Reduced Intensity Conditioning and Haploidentical Related Bone Marrow for Patients With Hematologic Diseases
Masonic Cancer Center, University of Minnesota
a Clinical Trial of Efficacy and Safety of the Holistic Treatment of Young High-risk Multiple Myeloma Patients
Institute of Hematology & Blood Diseases Hospital, China
Fludarabine Based Conditioning for Allogeneic Transplantation for Advanced Hematologic Malignancies
University of Illinois at Chicago
Umbilical Cord Blood (UCB) Transplantation in Pediatric Patients With High Risk Leukemia and Myelodysplasia
University of Miami
In-Vivo Activated T-Cell Depletion to Prevent GVHD
Indiana University
Natural Killer (NK) Cell Transplantation for AML
St. Jude Children's Research Hospital
UCALL
Baylor College of Medicine
Allogeneic Blood Stem Cell Transplantation
M.D. Anderson Cancer Center
Non-Myeloablative Allogeneic Stem Cell Transplantation
M.D. Anderson Cancer Center
Safety and Efficacy of Campath in Nonmyeloablative Transplantation
M.D. Anderson Cancer Center
Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Malignant Hematological Diseases
University of Oklahoma